ExRNA in Biofluids as Biomarkers for Brain Tumors.
ExRNA in Biofluids as Biomarkers for Brain Tumors.
复制标题
DOI：
10.1007/s10571-015-0284-5
复制
发表时间：
2016-04
影响因子：
4
通讯作者：
Carter BS
中科院分区：
文献类型：
--
作者：
Rennert RC;Hochberg FH;Carter BS
尽管有最佳的手术和药物治疗，高级别胶质瘤和胶质母细胞瘤(GBM)患者的存活率很低。微创的诊断生物标记物将使早期诊断和肿瘤特异性治疗成为“个性化靶向”治疗，并将为GBM患者的反应跟踪奠定基础。从脑脊液和血液中分离的细胞外小泡(EV)含有胶质瘤特异性分子，包括肿瘤来源的EV RNA，在这些生物液中可以检测到少量拷贝。EV RNA突变或表达变化也是可以检测到的，对这些变化的分析可以引起“液体活检”肿瘤侧写。
Patients with high-grade gliomas and glioblastomas (GBMs) have poor survival despite optimal surgical and drug therapy. Minimally invasive diagnostic biomarkers would enable early diagnosis and tumor-specific treatments for ‘personalized targeted’ therapy, and would create the basis for response tracking in patients with GBM. Extracellular vesicles (EVs) isolated from cerebrospinal fluid and blood contain glioma-specific molecules, including tumor-derived EV RNAs that are detectable in small copy numbers in these biofluids. EV RNA mutations or expression changes are also detectable, the analysis of which gives rise to ‘liquid biopsy’ tumor profiling.